Real-World Patient Perspectives on Glipizide and Empagliflozin for Type 2 Diabetes
Glipizide Vs Empagliflozin
DOI:
https://doi.org/10.66381/jod.2025.005Keywords:
Empagliflozin,, Glipizide, Diabetes Mellitus, Type II, Jardiance, Jardiance vs. GlipizideAbstract
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder requiring long-term pharmacological therapy. While Glipizide, a sulfonylurea, remains a common treatment option, newer agents such as Empagliflozin (Jardiance) offer potential additional benefits. Patient-reported experiences may provide valuable insights for optimizing treatment selection.
Methods: An anonymous, cross-sectional online survey was conducted among adults with T2DM who had prior exposure to both Glipizide and Empagliflozin. Participants answered four questions addressing perceived glycemic control, satisfaction, and treatment preference. Responses were summarized using descriptive statistics.
Results: A total of 39 patients completed the survey. The majority, 33 participants (85%), reported achieving better glycemic control with Glipizide, whereas 6 (15%) favored Empagliflozin. Satisfaction with Empagliflozin was mixed: 12 patients (31%) were disappointed, 20 (51%) were neutral, and 7 (18%) reported happiness with its use. In comparison, Glipizide was rated more positively, with 5 patients (13%) disappointed, 11 (28%) neutral, and 23 (59%) happy. When asked which medication they would recommend, 18 participants (46%) favored Empagliflozin, while 21 (54%) preferred Glipizide.
Conclusions: Glipizide was perceived to provide superior glycemic control and greater patient satisfaction compared with Empagliflozin. Nonetheless, nearly half of the participants recommended Empagliflozin despite lower ratings of satisfaction and efficacy. These findings suggest that patient preferences may extend beyond glycemic outcomes alone and highlight the importance of integrating patient-reported experiences into individualized treatment decisions for T2DM.
Downloads
References
1. Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS. 10th edition. Brussels: International Diabetes Federation; 2021. Chapter 1, What is diabetes? Available from: https://www.ncbi.nlm.nih.gov/books/NBK581938/
2. Sahin, I., Bakiner, O., Demir, T. et al. Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review. Diabetes Ther 15, 1687–1716 (2024). DOI: 10.1007/s13300-024-01612-8
3. Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. DOI:10.2337/dci22-0034
4. Madero M, Navaneethan SD, Agarwal R. SGLT2 inhibitor use in chronic kidney disease. Kidney Med. 2024;6(7):100798. DOI:10.1016/S2590-0595(24)00062-1.
5. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-24. DOI:10.1056/NEJMoa2022190.
6. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S300.
7. Barnard-Kelly, K., Battelino, T., Brosius, F.C. et al. Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop. Cardiovasc Diabetol 24, 68 (2025). DOI: 10.1186/s12933-024-02550-2
8. Stewart, K.D., Matza, L.S., Patel, H. et al. Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes. J Patient Rep Outcomes 7, 89 (2023). DOI: 10.1186/s41687-023-00614-7
9. Boye, K.S., Stewart, K.D. & Matza, L.S. Development of a Patient-Reported Outcome (PRO) Measure to Assess Emotional Impact of Treatment for Type 2 Diabetes. Diabetes Ther 14, 1451–1470 (2023). DOI: 10.1007/s13300-023-01426-0
10. Peimani, M., Stewart, A.L., Garmaroudi, G. et al. Shared decision-making in type 2 diabetes: a systematic review of patients’ preferences and healthcare providers’ perspectives. BMC Health Serv Res 25, 39 (2025). DOI: 10.1186/s12913-024-12160-z
11. Vaughan EM, Rueda JJ, Samson SL, Hyman DJ. Reducing the Burden of Diabetes Treatment: A Review of Low-cost Oral Hypoglycemic Medications. Curr Diabetes Rev. 2020;16(8):851-858. DOI:10.2174/1573399816666200206112318
12. Hasan I, Rashid T, Jaikaransingh V, Heilig C, Abdel-Rahman EM, Awad AS. SGLT2 inhibitors: Beyond glycemic control. J Clin Transl Endocrinol. 2024;35:100335. Published 2024 Mar 12. DOI:10.1016/j.jcte.2024.100335
13. Gajewska A, Wasiak J, Sapeda N, Młynarska E, Rysz J, Franczyk B. SGLT2 Inhibitors in Kidney Diseases-A Narrative Review. Int J Mol Sci. 2024;25(9):4959. Published 2024 May 1. DOI:10.3390/ijms25094959
14. Pouwer F, Hermanns N. Patient-reported outcomes in diabetes care. Diabet Med. 2022;39(1):e14734. DOI:10.1111/dme.14734.
Downloads
Published
Data Availability Statement
The data supporting the findings of this study are available from the corresponding author upon reasonable request. Individual responses have been anonymized to protect participant confidentiality.
License
Copyright (c) 2025 Journal of Diabesity
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Journal of Diabesity (JOD) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
What this means:
Under the CC BY 4.0 license, authors retain copyright of their work, while allowing others to:
-
Share — Copy and redistribute the material in any medium or format
-
Adapt — Remix, transform, and build upon the material for any purpose, even commercially
Conditions:
Users must provide appropriate attribution to the original author(s) and source, including:
-
The article title
-
Author(s) name(s)
-
Journal name (Journal of Diabesity)
-
DOI or link to the original article
-
An indication if changes were made
There is no restriction on commercial use or derivative works, as long as proper attribution is given.
Full License Text:
https://creativecommons.org/licenses/by/4.0/
✍️ Author Rights:
-
Authors retain copyright and grant JOD the right of first publication.
-
Authors may archive the published version in institutional repositories, personal websites, or other platforms with proper citation.
